Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 agents possess promising therapeutic results in treating type 2 dia